BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

UCB Canada Release: NEUPRO® (rotigotine) Now Available in Canada to Treat Parkinson's Disease


8/30/2013 8:34:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TORONTO, Aug. 29, 2013 /CNW/ - UCB Canada Inc. announced today that NEUPRO® (rotigotine) is now available in Canada for the treatment of Parkinson's disease.

The availability of NEUPRO® in Canada follows Health Canada's approval in March, making it the first new treatment for Parkinson's disease approved in Canada in five years. NEUPRO® is the first and only non-ergolinic dopamine agonist available in a patch, and provides 24-hour delivery of rotigotine through the skin into the blood stream. NEUPRO® has demonstrated efficacy in managing motor symptoms associated with Parkinson's disease.

"As a company committed to bringing meaningful medications to Canadians for serious medical conditions, such as Parkinson's disease, we are very pleased that NEUPRO® is a new option available by prescription from physicians," says Dr. Gordana Atanackovic, Director, Medical Affairs , UCB Canada Inc. "Based on clinical evidence and patient experience from numerous countries, we are confident that NEUPRO® can improve quality of life for many Canadians with Parkinson's disease which is very important for people struggling with its disruptive symptoms, such as on-off periods."

About Parkinson's disease
Parkinson's disease (PD) is a chronic, degenerative neurological disease which affects approximately 100,000 Canadians. PD develops with the loss of nerve cells in the brain that produce a chemical called dopamine. The symptoms of PD can have an impact on many dimensions of patients' lives. As dopamine levels fall, movement (motor) symptomstremors (uncontrollable shaking), rigidity (stiffness or muscle tensing) and bradykinesia (slowness and loss of spontaneous movement) can progress, along with the underlying symptoms of PD, which are less well recognized and may be under-treated.

About UCB Canada Inc.
Inspired by patients and driven by science, UCB Canada Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe auto-immune and central nervous system diseases. For more information, please consultwww.ucb.com/worldwide/canada.

SOURCE UCB Canada Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES